Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will evaluate the safety and performance of the Medtronic Hugo™ RAS System when used for urologic RAS procedures.
A prospective, multicenter, single-arm pivotal study in subjects undergoing a urologic RAS procedure using the Medtronic Hugo™ RAS System. Subjects without an oncologic indication will be followed for 30 days post-procedure. Oncologic subjects will be followed annually through 5 years. The study will be conducted in up to 6 investigative sites in the United States of America (USA).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Robotic Assisted Surgery (RAS) Urologic Surgery | Other | Robotic Assisted Surgery (RAS) urologic surgery under the umbrella of procedures outlined by the FDA (prostatectomy, cystectomy and nephrectomy). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| RAS Prostatectomy | Device | Subjects indicated for Robotic Assisted Surgery (RAS) for prostatectomy will have RAS surgery using the Medtronic Hugo RAS system. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Primary Effectiveness Endpoint - Surgical Success Rate, Defined as the Procedure Not Going Into Conversion | The primary effectiveness endpoint is the surgical success rate, defined as the procedure not going into conversion. Conversion is defined as the switch from a robotic assisted approach using the Hugo system to a robotic assisted approach utilizing an FDA cleared robotic-assisted device, laparoscopic, or open surgery. | During surgical procedure |
| Primary Safety Endpoint - Rate of Subjects With Complications Meeting Grade III - Grade V Criteria Per the Clavien-Dindo Classification System. | Complications meeting Grade III criteria or higher per the Clavien-Dindo Classification system, from first incision through 30 days post-procedure. Clavien-Dindo Classification of Surgical Complications: Grade I: Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic, and radiological interventions. Grade II: Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Blood transfusions and total parenteral nutrition are also included. Grade III: Requiring surgical, endoscopic or radiological intervention Grade IIIa: Intervention not under general anesthesia Grade IIIb: Intervention under general anesthesia Grade IV: Life-threatening complication requiring IC/ICU management Grade IVa: Single organ dysfunction (including dialysis) Grade IVb: Multiorgan dysfunction Grade V: Death of a patient | 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| Secondary Endpoint - Overall Complication Rate From First Incision Through 30 Days Post-procedure. | Complication rate: Overall rate of subjects with one or more complications (Clavien-Dindo Grade I or higher), from the first incision through 30 days post-procedure. | 30 days |
| Secondary Endpoint - Operative Time (Min) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Michael Abern, MD | Duke Medical Center | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | United States | ||
| University of Chiago |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42132526 | Derived | Abern MR, Wiklund P, Goh AC, Kaouk JH, Crivellaro S, Lau CS, Zhumkhawala AA, Huang R, Mehrazin R, Sfakianos JP, Madueke I, Inman BA, Blaser C, Masters M, Porter JR. The first United States prospective trial using the Hugo robot-assisted surgery system. BJU Int. 2026 Jul;138(1):85-91. doi: 10.1111/bju.70314. Epub 2026 May 14. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A total of 144 subjects were consented for enrollment. 7 subjects were discontinued from the study prior to their procedure.
There was no minimum enrollment requirement at each site; individual sites were not allowed to enroll more than 30% of the total study population. 137 subjects from 6 US sites contributed to the study cohort.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Robotic Assisted Surgery (RAS) Urologic Surgery - Prostatectomy | RAS Prostatectomy: Subjects indicated for Robotic Assisted Surgery (RAS) for prostatectomy will have RAS surgery using the Medtronic Hugo RAS system. |
| FG001 | Robotic Assisted Surgery (RAS) Urologic Surgery - Cystectomy |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Treatment |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Aug 21, 2024 | Oct 6, 2025 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| RAS Cystectomy | Device | Subjects indicated for Robotic Assisted Surgery (RAS) for cystectomy will have RAS surgery using the Medtronic Hugo RAS system. |
|
| RAS Nephrectomy | Device | Subjects indicated for Robotic Assisted Surgery (RAS) for nephrectomy (Radical/Partial) will have RAS surgery using the Medtronic Hugo RAS system. |
|
Operative time shall be collected through the length of the procedure. |
| up to 720 minutes |
| Secondary Endpoint - Intraoperative Estimated Blood Loss (mL). | Intraoperative estimated blood loss shall be collected through the length of the procedure. | intraoperative |
| Secondary Endpoint - Transfusion Rate Through 30 Days. | Transfusion rate shall be collected through 30 days post-procedure | 30 days |
| Secondary Endpoint - Rate of Device-related Conversions | Rate of device-related conversions shall be collected through the length of the procedure. | intraoperative |
| Secondary Endpoint - Hospital Length of Stay (Days) | Hospital length of stay (days) shall be collected through 30 days post-procedure. | 30 days |
| Secondary Endpoint - Readmission Rate (Through 30 Days) | Readmission rate shall be collected though 30 days post-procedure. | 30 days |
| Secondary Endpoint - Reoperation Rate (Through 30 Days). | Reoperation rate shall be collected through 30 days post-procedure. | 30 days |
| Secondary Endpoint - Mortality Rate (Through 30 Days). | Mortality rate shall be collected through 30 days post-procedure. | 30 days |
| Secondary Endpoint - Progression-free Survival | Progression-free survival rate will be assessed through 5 years in oncologic subjects. | 5 years |
| Secondary Endpoint - Disease-free Survival | Disease-free survival rate will be assessed through 5 years in oncologic subjects. | 5 years |
| Secondary Endpoint - Overall Survival | Overall survival rate will be assessed through 5 years in oncologic subjects. | 5 years |
| Chicago |
| Illinois |
| 60612 |
| United States |
| Mount Sinai | New York | New York | 10029 | United States |
| Duke Medical Center | Durham | North Carolina | 27710 | United States |
| Cleveland Clinic | Cleveland | Ohio | 44195 | United States |
| Swedish Medical Center | Seattle | Washington | 98122 | United States |
RAS Cystectomy: Subjects indicated for Robotic Assisted Surgery (RAS) for cystectomy will have RAS surgery using the Medtronic Hugo RAS system. |
| FG002 | Robotic Assisted Surgery (RAS) Urologic Surgery - Nephrectomy | RAS Nephrectomy: Subjects indicated for Robotic Assisted Surgery (RAS) for nephrectomy (Radical/Partial) will have RAS surgery using the Medtronic Hugo RAS system. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
| 30 Days |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Robotic Assisted Surgery (RAS) Urologic Surgery - Prostatectomy | RAS Prostatectomy: Subjects indicated for Robotic Assisted Surgery (RAS) for prostatectomy will have RAS surgery using the Medtronic Hugo RAS system. |
| BG001 | Robotic Assisted Surgery (RAS) Urologic Surgery - Cystectomy | RAS Cystectomy: Subjects indicated for Robotic Assisted Surgery (RAS) for cystectomy will have RAS surgery using the Medtronic Hugo RAS system. |
| BG002 | Robotic Assisted Surgery (RAS) Urologic Surgery - Nephrectomy | RAS Nephrectomy: Subjects indicated for Robotic Assisted Surgery (RAS) for nephrectomy (Radical/Partial) will have RAS surgery using the Medtronic Hugo RAS system. |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race/Ethnicity, Customized | Count of Participants | Participants | No |
| |||||||||||||||
| Region of Enrollment | Number | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Primary Effectiveness Endpoint - Surgical Success Rate, Defined as the Procedure Not Going Into Conversion | The primary effectiveness endpoint is the surgical success rate, defined as the procedure not going into conversion. Conversion is defined as the switch from a robotic assisted approach using the Hugo system to a robotic assisted approach utilizing an FDA cleared robotic-assisted device, laparoscopic, or open surgery. | One subject in the cystectomy cohort who met the criteria to be included in the Full Analysis set (FAS), as they received their first incision with intent of using Hugo, was excluded from the analysis as their procedure was aborted after an hour of exploration due to an advanced disease state. Data from the three RAS Urologic Surgery cohorts: Prostatectomy, Cystectomy, & Nephrectomy were combined for analysis per pre-specified analysis plan. | Posted | Count of Participants | Participants | During surgical procedure |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Primary Safety Endpoint - Rate of Subjects With Complications Meeting Grade III - Grade V Criteria Per the Clavien-Dindo Classification System. | Complications meeting Grade III criteria or higher per the Clavien-Dindo Classification system, from first incision through 30 days post-procedure. Clavien-Dindo Classification of Surgical Complications: Grade I: Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic, and radiological interventions. Grade II: Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Blood transfusions and total parenteral nutrition are also included. Grade III: Requiring surgical, endoscopic or radiological intervention Grade IIIa: Intervention not under general anesthesia Grade IIIb: Intervention under general anesthesia Grade IV: Life-threatening complication requiring IC/ICU management Grade IVa: Single organ dysfunction (including dialysis) Grade IVb: Multiorgan dysfunction Grade V: Death of a patient | Three subjects (1 prostatectomy, 1 cystectomy, 1 nephrectomy) had a missed 30-day follow-up visit. Subjects must have met one of the following conditions to be included:
| Posted | Count of Participants | Participants | 30 days |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Secondary Endpoint - Overall Complication Rate From First Incision Through 30 Days Post-procedure. | Complication rate: Overall rate of subjects with one or more complications (Clavien-Dindo Grade I or higher), from the first incision through 30 days post-procedure. | Subjects must have met one of the following conditions to be included:
| Posted | Count of Participants | Participants | 30 days |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Secondary Endpoint - Operative Time (Min) | Operative time shall be collected through the length of the procedure. | Operative time, an efficacy measure, is reported only for subjects whose procedures were completed as planned using the Hugo system. This measure excludes aborted cases (n=1 cystectomy) and converted cases (n=2 nephrectomies). | Posted | Mean | Standard Deviation | Minutes | up to 720 minutes |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Secondary Endpoint - Intraoperative Estimated Blood Loss (mL). | Intraoperative estimated blood loss shall be collected through the length of the procedure. | Intraoperative Estimated Blood loss, as a safety measure, is reported for all subjects in whom Hugo was utilized during the procedure. | Posted | Mean | Standard Deviation | mL | intraoperative |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Secondary Endpoint - Transfusion Rate Through 30 Days. | Transfusion rate shall be collected through 30 days post-procedure | Transfusion rate, as a safety measure, is reported for all subjects in whom Hugo was utilized during the procedure. | Posted | Count of Participants | Participants | 30 days |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Secondary Endpoint - Rate of Device-related Conversions | Rate of device-related conversions shall be collected through the length of the procedure. | Rate of Device Related Conversions is reported for all subjects in whom Hugo was utilized during the procedure. | Posted | Count of Participants | Participants | intraoperative |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Secondary Endpoint - Hospital Length of Stay (Days) | Hospital length of stay (days) shall be collected through 30 days post-procedure. | Hospital Length of Stay is reported for all subjects in whom Hugo was utilized during the procedure. | Posted | Mean | Standard Deviation | Days | 30 days |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Secondary Endpoint - Readmission Rate (Through 30 Days) | Readmission rate shall be collected though 30 days post-procedure. | Readmission rate, as a safety measure, is reported for all subjects in whom Hugo was utilized during the procedure. | Posted | Count of Participants | Participants | 30 days |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Secondary Endpoint - Reoperation Rate (Through 30 Days). | Reoperation rate shall be collected through 30 days post-procedure. | Reoperation rate, as a safety measure, is reported for all subjects in whom Hugo was utilized during the procedure. | Posted | Count of Participants | Participants | 30 days |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Secondary Endpoint - Mortality Rate (Through 30 Days). | Mortality rate shall be collected through 30 days post-procedure. | Posted | Count of Participants | Participants | 30 days |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Secondary Endpoint - Progression-free Survival | Progression-free survival rate will be assessed through 5 years in oncologic subjects. | Not Posted | Jan 2030 | 5 years | Participants | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Secondary Endpoint - Disease-free Survival | Disease-free survival rate will be assessed through 5 years in oncologic subjects. | Not Posted | Jan 2030 | 5 years | Participants | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Secondary Endpoint - Overall Survival | Overall survival rate will be assessed through 5 years in oncologic subjects. | Not Posted | Jan 2030 | 5 years | Participants |
All Adverse Events were collected from the time of consent through 30 days post procedure.
All participant deaths within the database snapshot were included.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Robotic Assisted Surgery (RAS) Urologic Surgery - Prostatectomy | RAS Prostatectomy: Subjects indicated for Robotic Assisted Surgery (RAS) for prostatectomy will have the RAS surgery using the Medtronic Hugo RAS system. | 1 | 55 | 5 | 55 | 19 | 55 |
| EG001 | Robotic Assisted Surgery (RAS) Urologic Surgery - Cystectomy | RAS Cystectomy: Subjects indicated for Robotic Assisted Surgery (RAS) for cystectomy will have the RAS surgery using the Medtronic Hugo RAS system. | 1 | 29 | 15 | 29 | 7 | 29 |
| EG002 | Robotic Assisted Surgery (RAS) Urologic Surgery - Nephrectomy | RAS Nephrectomy: Subjects indicated for Robotic Assisted Surgery (RAS) for nephrectomy (Radical/Partial) will have RAS surgery using the Medtronic Hugo RAS system. | 0 | 53 | 7 | 53 | 6 | 53 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Cardiac Arrest | Cardiac disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Tachycardia | Cardiac disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Abdominal Hernia | Gastrointestinal disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Ileus | Gastrointestinal disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Intestinal Perforation | Gastrointestinal disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Melaena | Gastrointestinal disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Death | General disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Oedema Peripheral | General disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Bacteraemia | Infections and infestations | MedDRA 27.0 | Systematic Assessment |
| |
| Peritonitis | Infections and infestations | MedDRA 27.0 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA 27.0 | Systematic Assessment |
| |
| Pyelonephritis | Infections and infestations | MedDRA 27.0 | Systematic Assessment |
| |
| Sepsis | Infections and infestations | MedDRA 27.0 | Systematic Assessment |
| |
| Urinary Tract Infection | Infections and infestations | MedDRA 27.0 | Systematic Assessment |
| |
| Urosepsis | Infections and infestations | MedDRA 27.0 | Systematic Assessment |
| |
| Anaemia Postoperative | Injury, poisoning and procedural complications | MedDRA 27.0 | Systematic Assessment |
| |
| Arterial Injury | Injury, poisoning and procedural complications | MedDRA 27.0 | Systematic Assessment |
| |
| Gastrointestinal Injury | Injury, poisoning and procedural complications | MedDRA 27.0 | Systematic Assessment |
| |
| Incision Site Haematoma | Injury, poisoning and procedural complications | MedDRA 27.0 | Systematic Assessment |
| |
| Post Procedural Haematoma | Injury, poisoning and procedural complications | MedDRA 27.0 | Systematic Assessment |
| |
| Post Procedural Urine Leak | Injury, poisoning and procedural complications | MedDRA 27.0 | Systematic Assessment |
| |
| Procedural Haemorrhage | Injury, poisoning and procedural complications | MedDRA 27.0 | Systematic Assessment |
| |
| Wound Dehiscence | Injury, poisoning and procedural complications | MedDRA 27.0 | Systematic Assessment |
| |
| Post Procedural Hameorrhage | Injury, poisoning and procedural complications | MedDRA 27.0 | Systematic Assessment |
| |
| Dehydration | Metabolism and nutrition disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Hyperkalaemia | Metabolism and nutrition disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Hypernatraemia | Metabolism and nutrition disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Hypoalbuminaemia | Metabolism and nutrition disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Hypocalcaemia | Metabolism and nutrition disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Hyponatraemia | Metabolism and nutrition disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Syncope | Nervous system disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Acute Kidney Injury | Renal and urinary disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Haematuria | Renal and urinary disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Urinary Incontinence | Renal and urinary disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Acute Respiratory Failure | Respiratory, thoracic and mediastinal disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Atelectasis | Respiratory, thoracic and mediastinal disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Hypoxia | Respiratory, thoracic and mediastinal disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Pulmonary Embolism | Respiratory, thoracic and mediastinal disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Pulmonary Oedema | Respiratory, thoracic and mediastinal disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Umbilical Haematoma | Skin and subcutaneous tissue disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Deep Vein Thrombosis | Vascular disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Lymphocele | Vascular disorders | MedDRA 27.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal Pain | Gastrointestinal disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Back Pain | Musculoskeletal and connective tissue disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Urinary Incontinence | Renal and urinary disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Erectile Dysfunction | Reproductive system and breast disorders | MedDRA 27.0 | Systematic Assessment |
|
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Michele Masters, Sr. Clinical Research Program Manager | Medtronic | 4848948925 | michele.masters@medtronic.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Nov 4, 2024 | Oct 6, 2025 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D001749 | Urinary Bladder Neoplasms |
| D011471 | Prostatic Neoplasms |
| D007680 | Kidney Neoplasms |
| D010386 | Pelvic Neoplasms |
| D018856 | Cystitis, Interstitial |
| D000013 | Congenital Abnormalities |
| D007676 | Kidney Failure, Chronic |
| D002292 | Carcinoma, Renal Cell |
| ID | Term |
|---|---|
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D001745 | Urinary Bladder Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
| D005834 | Genital Neoplasms, Male |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D011469 | Prostatic Diseases |
| D007674 | Kidney Diseases |
| D003556 | Cystitis |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D051436 | Renal Insufficiency, Chronic |
| D051437 | Renal Insufficiency |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
| Between 18 and 65 years |
|
| >=65 years |
|
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Black or African American |
|
| Asian |
|
| American Indian or Alaska Native |
|
| Other |
|
| Unknown |
|
| Not Reported |
|
| Native American or Other Pacific Islander |
|
| OG001 | Robotic Assisted Surgery (RAS) Urologic Surgery - Cystectomy | RAS Cystectomy: Subjects indicated for Robotic Assisted Surgery (RAS) for cystectomy will have RAS surgery using the Medtronic Hugo RAS system. |
| OG002 | Robotic Assisted Surgery (RAS) Urologic Surgery - Nephrectomy | RAS Nephrectomy: Subjects indicated for Robotic Assisted Surgery (RAS) for nephrectomy (Radical/Partial) will have RAS surgery using the Medtronic Hugo RAS system. |
|
|
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Units | Counts |
|---|
| Participants |
|
|
| Units | Counts |
|---|
| Participants |
|
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
|
| Units | Counts |
|---|
| Participants |
|
|
| Units | Counts |
|---|
| Participants |
|
|
|
|